top of page

Eiger BioPharmaceuticals


Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA. The listed name for EIGR is Eiger BioPharmaceuticals, Inc. Common Stock.

bottom of page